Summary:
- Ultragenyx, a biopharmaceutical company, presented positive updates on its GTX-102 Angelman syndrome program at the FAST's 17th Annual Global Science Summit.
- GTX-102 is an investigational antisense oligonucleotide therapy designed to treat Angelman syndrome, a rare genetic neurological disorder that affects approximately 1 in 15,000 people.
- The update includes data from the ongoing Phase 1/2 clinical trial, which showed improvements in developmental milestones and adaptive behaviors in patients with Angelman syndrome, indicating the potential of GTX-102 as a treatment option.